XORTX Therapeutics Q1 2024 Earnings Steep EPS Miss Highlights PreRevenue Biotech Hurdles Standard Chartered to Reduce Corporate Functions Roles by Over 15 in Push for Higher Returns Fed Minutes Signal Extended Rate Hold Potential Hikes if Inflation Remains Sticky SpaceX Scrubs Starship Test Launch IPO Filing Highlights Rocket Dependency DHCNL Q1 2026 Earnings WiderthanExpected Loss Weighs on Senior Note Performance Standard Chartered to Reduce Corporate Functions Roles by Over 15 in Push for Higher Returns